A detailed history of Auxier Asset Management transactions in Alkermes Plc. stock. As of the latest transaction made, Auxier Asset Management holds 11,891 shares of ALKS stock, worth $353,281. This represents 0.05% of its overall portfolio holdings.

Number of Shares
11,891
Previous 11,891 -0.0%
Holding current value
$353,281
Previous $286,000 16.08%
% of portfolio
0.05%
Previous 0.05%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$26.4 - $32.56 $34,320 - $42,328
-1,300 Reduced 9.86%
11,891 $321,000
Q3 2023

Nov 21, 2023

SELL
$27.17 - $31.97 $8,151 - $9,591
-300 Reduced 2.22%
13,191 $369,000
Q1 2023

May 15, 2023

SELL
$25.31 - $29.02 $1,265 - $1,451
-50 Reduced 0.37%
13,491 $380,000
Q4 2022

Feb 17, 2023

SELL
$21.94 - $26.24 $26,328 - $31,487
-1,200 Reduced 8.14%
13,541 $353,000
Q2 2022

Aug 11, 2022

SELL
$26.4 - $30.54 $52,800 - $61,080
-2,000 Reduced 11.95%
14,741 $439,000
Q1 2022

May 17, 2022

SELL
$23.07 - $27.99 $8,074 - $9,796
-350 Reduced 2.05%
16,741 $440,000
Q4 2021

Mar 01, 2022

SELL
$21.47 - $32.08 $49,917 - $74,586
-2,325 Reduced 11.97%
17,091 $398,000
Q2 2021

Aug 18, 2021

SELL
$18.78 - $25.15 $94,839 - $127,007
-5,050 Reduced 20.64%
19,416 $476,000
Q1 2021

May 17, 2021

SELL
$18.21 - $23.2 $52,809 - $67,280
-2,900 Reduced 10.6%
24,466 $457,000
Q3 2020

Mar 05, 2021

SELL
$16.16 - $20.66 $404 - $516
-25 Reduced 0.09%
27,366 $453,000
Q1 2020

May 15, 2020

SELL
$13.06 - $21.24 $1,306 - $2,124
-100 Reduced 0.36%
27,391 $395,000
Q4 2019

Feb 21, 2020

SELL
$17.29 - $21.74 $1,037 - $1,304
-60 Reduced 0.22%
27,491 $561,000
Q3 2019

Nov 15, 2019

SELL
$19.51 - $24.28 $1,951 - $2,428
-100 Reduced 0.36%
27,551 $538,000
Q3 2018

Nov 19, 2018

BUY
$38.6 - $46.12 $38,600 - $46,120
1,000 Added 3.75%
27,651 $1.17 Million
Q2 2017

Aug 16, 2017

BUY
N/A
26,651
26,651 $1.55 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.88B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Auxier Asset Management Portfolio

Follow Auxier Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Auxier Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Auxier Asset Management with notifications on news.